A tad bemusing isn't it. Biotech has been a difficult space along with small cap. I noted a CNBC interview recently identified Biotech opportunities but more at the big end. I think if a smaller company released a sensitive announcement like CUV regarding Parkinson's, you would have had a significant lift 20-30% perhaps even today. Not sure why they are not buying more back at these levels either?? I guess the worry for me is despite recent news and road shows there's been little significant buying? Anyway, they ticked another box and I'm hoping the full year is better than the conservative growth I forecast. Perhaps 25/26 will be pivotal in the recovery.
A tad bemusing isn't it. Biotech has been a difficult space...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.73 |
Change
-0.470(3.31%) |
Mkt cap ! $687.3M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.00 | $13.69 | $929.6K | 67.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.74 | 169 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |